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 CURRENTOPINION TBX4 variants and pulmonary diseases: getting
out of the ‘Box’
Meindina G. Haarmana, Wilhelmina S. Kerstjens-Frederikseb,
and Rolf M.F. Bergera
Purpose of review
In 2013, the association between T-Box factor 4 (TBX4) variants and pulmonary arterial hypertension (PAH)
has first been described. Now – in 2020 – growing evidence is emerging indicating that TBX4 variants
associate with a wide spectrum of lung disorders.
Recent findings
TBX4 variants are enriched in both children and adults with PAH. The clinical phenotype associated with a
TBX4 variant seems to be milder than that in other PAH-associated gene mutations. Further, TBX4 variants
have increasingly been associated with a variety of clinical and histopathological phenotypes, including
lethal developmental parenchymal lung diseases such as not only acinar dysplasia in neonates, but also
less outspoken parenchymal lung diseases in children and adults.
Summary
The clinical phenotype of a TBX4 variant has recently been recognised to expand from bone disorders to
different types of lung diseases. Recent data suggest that variants of TBX4, a transcription factor known to
be an important regulator in embryonic development, are not rare in both children and adults with PAH
and/or developmental parenchymal lung diseases.
Keywords
lung disease, pulmonary arterial hypertension, T-Box factor 4
INTRODUCTION
In 1927, Nadezhda Alexandrovna Dobrovolskaya-
Zavadskaya described a heterozygous mutation in
mice that affected both tail length and the sacral
vertebrae [1]. This mutation was called brachyury
(short tail, Greek) mutation. Later, because of the
T(tail)-locus of the gene product, the mutation
was renamed into T-Box mutation [2,3]. In 1996,
T-Box transcription factor 4 (TBX4) was identi-
fied, in a series of other T-Box genes (TBX1–5), as
a gene highly expressed during organogenesis
[4,5].
This review deepens into the TBX4 gene and
its variants in pulmonary diseases, since in the
recent years, the spectrum of clinical phenotypes
associated with variants of the TBX4 gene [inclu-
ding both mutations and copy number variations
(CNVs)] is expanding from bone abnormalities to
conditions affecting other organs, especially the
lungs. We aim to discuss the current knowledge
on the role of TBX4 variants in human lung
diseases.
EMBRYOGENESIS
T-Box genes are DNA-binding transcription factors
that play a crucial role during embryogenesis [6].
The TBX4 gene is located on chromosome 17q23.2
and has shown to be important for hindlimb
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REVIEW
and pelvic development in both animals and
humans [5,7,8]. Animal studies have also suggested
an important role for TBX4 in the formation of the
body wall, development of external genitalia and
anorectal development [5,9,10].
In addition, TBX4 is expressed in the lung me-
senchyme, already at an early stage during embryo-
genesis [10]. Together with TBX5, TBX4 regulates
the process of lung branching by controlling the
expression of the secreted fibroblast growth factor
(FGF)10 and activation of FGF10 signalling [11,12].
FGF10 is expressed in the mesenchyme surrounding
the distal epithelial tips that mark the site of future
bud formation and acts by mainly binding to the
FGF receptor 2b [13–15]. FGF10 is involved in the
initial production of paired buds of endoderm from
the ventral foregut and their eventual outgrowth
forming the precursors of the main bronchi [14].
Second, FGF10 induces new bud formation and
therefore plays a key role in branching morphoge-
nesis [14,16].
Another important regulatory gene that is
affected by TBX4 and TBX5 signalling is canonical
wingless-2 (WNT2), a mesenchymal protein that is
essential for lung specification [11,17].
Reduction of TBX4 or TBX5 leads to a severe
decrease in branching by a loss of expression of both
FGF10 and WNT2. This results in a defect of forma-
tion of lung lobes and failure of lung lobe separa-
tion, eventually leading to a smaller overall lung size
[11,18]. Absence of both TBX4 and TBX5 leads to
complete branching arrest [19].
In addition, TBX4 and TBX5, via SOX9 and
independently of the FGF10 signalling pathway,
regulate the condensation of cells to form the
cartilage rings of the trachea and bronchi, and also
the development of the smooth muscle cells in the
trachea [11,20]. Reduction of both TBX4 and TBX5
causes a decreased number of tracheal cartilage
rings and can therefore result in tracheomalacia
or tracheal stenosis [11]. TBX4 has also been shown
to be present in pulmonary veins and arteries,
suggesting that pulmonary vessels arise from the
surrounding lung mesenchyme [10]. These experi-
mental data, derived from cell and animal studies,
indicate rather convincingly that TBX4 plays an
important role in foetal development, including
both parenchymal and vascular lung development.
CLINICAL PHENOTYPES
Clinical consequences of TBX4 variants in humans
were first revealed in 2004, when the association
between a spectrum of limb and skeletal abnormali-
ties, known as small patella syndrome (SPS) or
ischiocoxopodopatellar syndrome, was identified
(Fig. 1) [22]. This syndrome causes aplasia or hypo-
plasia of the patella and developmental anomalies
of the pelvis and feet.
In 2013, Kerstjens-Frederikse et al. [23] disco-
vered that mutations in the TBX4 gene or deletions
encompassing the TBX4 gene were associated
with pulmonary arterial hypertension (PAH) in
childhood. Pulmonary hypertension, an increased
pulmonary arterial pressure, is a haemodynamic
symptom, and its underlying diseases are charac-
terised by a clinical classification (Table 1) [24,25].
PAH is a specific formof PH and is a rare, progressive
and often lethal disease of the pulmonary vascula-
ture, characterised by an increased pulmonary vas-
cular resistance, leading to right ventricular failure
and eventually death [26,27]. It may be associated
with a variety of underlying diseases, including
connective tissue diseases, congenital heart di-
seases, portal hypertension, HIV infection and
drugs. In the absence of associated conditions, it
is classified as idiopathic PAH (IPAH) or it can be
caused by a genetic defect (hereditary PAH; HPAH)
(Table 1) [24,25]. In recent years, a progressive
number of gene mutations is being been identified
as cause for PAH, including mutations in bone
morphogenetic protein receptor type II (BMPR2)
being the most frequently found gene mutation
in both children and adults with PAH [28–30].
Further, mutations in activin receptor-like kinase
1 (ACVRL1), endoglin (ENG), potassium channel
subfamily K member 3 (KCNK3), eukaryotic trans-
lation initiation factor 2-alpha kinase 4 (EIF2AK4),
Caveolin-1 (CAV1) and SMAD9 have currently been
identified as associated with the occurrence of PAH,
and this list is growing [31–36].
KEY POINTS
 TBX4 variants are associated with idiopathic and
hereditary pulmonary arterial hypertension (IPAH/
HPAH) and seem to be enriched in children compared
with adults.
 TBX4 variants are associated with a variety of
parenchymal lung diseases, ranging from lethal
neonatal developmental lung diseases, including acinar
dysplasia and congenital alveolar dysplasia, to milder
forms of growth abnormalities.
 Both infants, children and adults can present with TBX4-
associated parenchymal lung diseases.
 The presence of parenchymal lung disease in a patient
with TBX4-associated pulmonary hypertension (PH) may
complicate clinical classification of the patient in HPAH
or group 3 PH associated with developmental
lung disease.
Genetics
278 www.co-pulmonarymedicine.com Volume 26  Number 3  May 2020
In the study of Kerstjens-Frederikse et al. [23],
genetic analyses in a cohort of 20 children with
IPAH revealed deletions at 17q23.2 with an over-
lapping region harbouring the TBX4 gene in three
children with PAH and mental retardation, and an
intragenic TBX4 mutation in three children with
PAH with normal intelligence. All appeared to have
skeletal malformations characteristic for SPS.
Since the discovery of the association between
TBX4 variants and paediatric PAH, different cohorts
confirmed an enrichment of TBX4 variants in child-
hood P(A)H. Levy et al. [33] reported three TBX4
truncating mutations in a subgroup of 40 paediatric
IPAH/HPAH patients (8%). Zhu et al. [37
&
] found in a
cohort of 155 patients with paediatric-onset IPAH/
HPAH that TBX4 variants were present in a substan-
tial proportion of children (8%). Of these, 5% were
pathogenic and likely pathogenic (LP) variants in
TBX4, while another 3% were variants of unknown
significance (VUS).
In summary, the prevalence of TBX4 variants
in children with IPAH/HPAH is estimated 7–8%,
which makes TBX4, after BMPR2, the second




A lower number of TBX4 variants seemed to be
present in the adult population with IPAH/HPAH.
Kerstjens-Frederikse et al. [23] in the same study, as
previously mentioned, identified two TBX4 variants
(one LP, one VUS) in a cohort of 49 adults with
IPAH. In a larger cohort of 257 adults with IPAH/
HPAH, Zhu et al. [37
&
] identified three adult patients
with aTBX4 variant (one LP, twoVUS) (1.2%). Navas
et al. [39] reported a prevalence of 2.4% of TBX4
variants in patients with IPAH/HPAH. In a cohort of
966 adult patients with IPAH/HPAH, Gra¨f et al. [40]
reported that 1.4% of the patients had a TBX4 vari-
ant. Finally, in a French cohort, Eyries et al. [38]
reported that 2.6% of the patients with IPAH/HPAH
had a TBX4 variant, concluding that also in adult-
hood PAH, TBX4 may be the most frequently
mutated gene after BMPR2. In summary, the overall
prevalence of TBX4 variants in adults with IPAH/
HPAH is estimated around 1.7%.
The reason why TBX4 variants seem to be more
frequent in childhood-onset compared with adult-
hood-onset IPAH/HPAH is insufficiently clear. A
detrimental disease course of TBX4-associated
HPAH with early decease before reaching adulthood
would have explained such phenomenon, however
FIGURE 1. Timeline of the expanding clinical phenotypes of TBX4 variants since the discovery of this gene in 1996.
Reproduced with permission from [21].
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currently available, preliminary outcome data inva-
lidate such speculation. The clinical implications of
the presence of TBX4 variants in children with PAH
have been scarcely studied. Where BMPR2mutation
carriers have shown to have a worse survival in both
children and adults with HPAH when compared
with noncarriers, children with TBX4 variants in a
Dutch national cohort of 70 children with PAH
showed less severe clinical presentation and more
favourable survival compared with BMPR2mutation
carriers, similar to nonmutation carriers (own data).
Similar findings have been reported by Levy et al.
[33] in a French cohort of 66 children with PAH.
Navas et al. [39] confirmed these findings in
adults with IPAH/HPAH and showed that patients
with a TBX4 variant tended to have a milder clinical
presentation compared with patients with IPAH,
BMPR2 mutation carriers, KCNK3 mutation carriers
and patients with familial PAH without a mutation.
Also, survival in patients with a TBX4 variant was
better compared with patients with a BMPR2 muta-
tion or a KCNK3 mutation.
Zhu et al. [37
&
] reported that HPAH patients
carrying a TBX4 variant had a 20-year younger
age-of-onset than BMPR2 mutation carriers
(mean SD: 7.99.0 compared with 28.215.4,
respectively, P<0.0001). Although the clinical phe-
notype of PAH in TBX4 variant carriers in general
seems to bemilder than in BMPR2mutation carriers,
it is not necessarily favourable, and varies from
mild/moderate PAH to also more severe forms of




Until today, available clinical data do not justify
patients withHPAHharbouring aTBX4 variant to be
treated differently than patients with other forms of
PAH-associated conditions.
TBX4 AND PARENCHYMAL LUNG
DISEASES
After the first discovery of a role for TBX4 variants in
the development of PAH, Szafranski et al. [41]
described in 2016 a neonate with signs of acinar
dysplasia (AcDys), a severe diffuse developmental
lung disease, who showed to have a de novo TBX4
mutation. This was the first report suggesting a
relation between a TBX4 variant and developmental
parenchymal lung disease. Subsequently, in 2019,
German et al. [42] described another case of a pre-
term born neonate with respiratory failure due to a
diagnosis of AcDys, harbouring a deletion from
chromosome 17q23.2 to 17q23.2 involving 14 genes
including TBX4 (Fig. 2). In the same year, Karolak
et al. [43
&&
] described a cohort of 26 children with
AcDys, congenital alveolar dysplasia (CAD) or other
rare pulmonary hypoplasias and reported in 16 chil-
dren, a TBX4 variant or FGF10 variant. In almost
50% of these cases, the developmental lung disease
was accompanied by PH. Suhrie et al. [44] identified
pathogenic TBX4 mutations in two cases of infants
presenting with respiratory failure. One child had
abnormal lung lobulation with marked deficiency
in acinar/alveolar development, and eventually
deceased. The other child had a lung biopsy that
demonstrated areas of the lung with near normal
alveolarisation adjacent to regions with deficient
alveolar growth, characterised by simplified, cysti-
cally dilated alveolar spaces [45].
Galambos et al. [46
&&
] subsequently further
extended the spectrum of paediatric diffuse paren-
chymal lung disease associated with TBX4 variants.
The authors described a cohort of 19 children with
TBX4 variants, including six children with loss of
the TBX4 gene due to 17q23 deletions and thirteen





1.3 Drug- and toxin-induced PAH
1.4 PAH associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.5 PAH longterm responders to calcium channel blockers
1.6 PAH with overt features of venous/capillaries (PVOD/PCH)
involvement
1.7 Persistent PH of the newborn syndrome
2 PH due to left heart disease
2.1 PH due to heart failure with preserved LVEF
2.2 PH due to heart failure with reduced LVEF
2.3 Valvular heart disease
2.4 Congenital/acquired cardiovascular conditions leading to
postcapillary PH
3 PH due to lung diseases and/or hypoxia
3.1 Obstructive lung disease
3.2 Restrictive lung disease
3.3 Other lung disease with mixed restrictive/obstructive pattern
3.4 Hypoxia without lung disease
3.5 Developmental lung disorders
4 PH due to pulmonary artery obstructions
4.1 Chronic thromboembolic PH
4.2 Other pulmonary artery obstructions
5 PH with unclear and/or multifactorial mechanisms
5.1 Haematological disorders
5.2 Systemic and metabolic disorders
5.3 Others
5.4 Complex congenital heart disease
LVEF, left ventricular ejection fraction; PAH, pulmonary arterial hypertension;
PCH, pulmonary capillary haemangiomatosis; PVOD, pulmonary veno-
occlusive disease.
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children with intragenic mutations. The majority of
the children (63%) presentedwith a biphasic clinical
course of neonatal hypoxic respiratory failure and
persistent pulmonary hypertension of the neonate
(PPHN), which seemed to resolve around the age of 1
month, but followed by chronic PH later in infancy
or early childhood. Histopathological assessment
was available in seven children and showed mainly
signs of severe disruption of all compartments of
distal lung development similar to CAD or AcDys, or
signs of pulmonary interstitial glycogenosis (PIG).
The children with a severe presentation of PPHN in
the beginning of their life also showed more severe
disruption of the distal lung development compared
with children who were diagnosed later in child-
hood. Some children had prominent interstitial
lung disease. This series unequivocally shows that
TBX4 variants are not only associated with lethal
developmental lung diseases such as AcDys or CAD,
but may also present with milder growth abnorma-
lities or nonspecific interstitial lung diseases. Inte-
restingly, a recent case report of Maurac et al. [47
&
]
suggests that such developmental growth anomalies
are not necessarily associated with neonatal presen-
tation. The authors describe a 34-year-old woman
presenting with unexplained PAH and right heart
failure [47
&
]. On x-rays of the feet and the pelvis, the
patient showed signs of SPS. Chest computed
tomography (CT) revealed peripheral reticular lines,
centrilobular nodules, thin-walled cysts in the upper
lobes and an appearance resembling diverticula in
the trachea and large bronchi. Lung biopsy from the
left upper lobe showed densification foci of the lung
parenchyma with cholesterol crystals. Although the
histopathological abnormalities were not typical for
developmental distal lung abnormalities, the
tracheal abnormalities in this patient highlight a
potential role ofTBX4 in a disturbed development of
the larger airways [11].
The studies described here strongly suggest that
TBX4 variants can be associated with a broad spec-
trum of lung diseases with a wide age range of
clinical presentations. Neonates and infants with
TBX4 variants are clearly overrepresented in the
reports on parenchymal lung diseases and authors
have frequently used the terminology ‘developmen-
tal lung disease’. Different classifications for chil-
dren’s interstitial and diffuse lung disease (chILD)
have been proposed. The American Thoracic Society
published a classification of chILD in 2013 where
AcDys, CAD, alveolar capillary dysplasia with mis-
alignment of pulmonary veins (ACDMPV) are clas-
sified as diffuse developmental disorders, whereas
primary pulmonary hypoplasia is classified under
growth abnormalities (Table 2) [48,49
&
]. The struc-
tural changes seen in these diseases are associated
with the different stages during lung embryogenesis
in which growth arrest occurs; the pseudoglandular
(AcDys), canalicular (CAD) and saccular/alveolar
(both ACDMPV and primary pulmonary hypopla-
sia) phase [50
&&
]. Also, PIG, characterised by intersti-
tial expansion due to increased mesenchymal
cellularity, is regarded a disease of altered lung
development [49
&
,51]. Also, other diffuse lung di-
seases such as chronic neonatal lung disease (i.e.
bronchopulmonary dysplasia), or surfactant dys-
function disorders (i.e. nonspecific interstitial pneu-
monia) are associated with disturbed or disrupted






ChILD is a complex spectrum of disorders with a
high variety in clinical phenotypes for which the
FIGURE 2. Lung histopathology of a patient with acinar dysplasia. (a) Lung from the infant’s autopsy, showing an immature
appearance for gestational age with no saccular structures or alveoli. (b) Higher power demonstrating abnormal acinar
structures with abundant intervening mesenchyme (hematoxylin and eosin). Reproduced with permission from [42].
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associated pathophysiology is insufficiently under-
stood. Therefore, although the notable role of TBX4
in embryonic development may be tempting, the
term ‘developmental lung disease’ as a common
denominator in the phenotypical spectrum of
TBX4-associated lung diseases should be used
with caution.
The reason for the variety in clinical presenta-
tion in patients carrying a TBX4 variant remains
unclear. It has been hypothesised that the type of
mutation may determine both phenotype and its
severity, but currently, there does not seem to be a





]. Genetic modifiers – co-
ding or noncoding – may play a role in the variabi-
lity of the phenotype. Karolak et al. demonstrated
that all infants with developmental lung disease
with either a TBX4 variant or FGF10 variant also
harboured at least one noncoding mutation in
BCAS3 (microtubule associated cell migration fac-
tor), which has overlap with the predicted regula-
tory elements that have been identified in the
human foetal lung fibroblast cell line [43
&&
,52].
However, children with deletions of chromosome
17q23.2, harbouring both TBX4 and BCAS3, do not
necessarily present with lung disease or PAH [45].
Table 2. Classification scheme for paediatric diffuse lung disease [48]
I. Disorders more prevalent in infancy
A. Diffuse developmental disorders
1. Acinar dysplasia
2. Congenital alveolar dysplasia
3. Alveolar-capillary dysplasia with pulmonary vein misalignment
B. Growth abnormalities
1. Pulmonary hypoplasia
2. Chronic neonatal lung disease
A. Prematurity-related chronic lung disease (bronchopulmonary dysplasia)
B. Acquired chronic lung disease in term infants
3. Structural pulmonary changes with chromosomal abnormalities
A. Trisomy 21
B. Others
4. Associated with congenital heart disease in chromosomally normal children
C. Specific conditions of undefined aetiology
1. Pulmonary interstitial glycogenosis
2. Neuroendocrine cell hyperplasia of infancy
D. Surfactant dysfunction mutations and related disorders
1. SPFTB genetic mutations – PAP and variant dominant histologic pattern
2. SPFTC genetic mutations – CPI dominant histologic pattern; also DIP and NSIP
3. ABCA3 genetic mutations – PAP variant dominant pattern; also CPI, DIP, NSIP
4. Others with histology consistent with surfactant dysfunction disorder without a yet recognised genetic disorder
II. Disorders not specific to infancy
A. Disorders of the normal host
1. Infectious and postinfectious processes
2. Disorders related to environmental agents: hypersensitivity pneumonia, toxic inhalation
3. Aspiration syndromes
4. Eosinophilic syndromes




4. Langerhans cell histiocytosis
5. Malignant infiltrates
C. Disorders of the immunocompromised host
1. Opportunistic infection
2. Disorders related to therapeutic intervention
3. Disorders related to transplantation and rejection syndromes
4. Diffuse alveolar damage of unknown aetiology
D. Disorders masquerading as interstitial disease
1. Arterial hypertensive vasculopathy
2. Congestive vasculopathy, including veno-occlusive disease
3. Lymphatic disorders
4. Congestive changes related to cardiac dysfunction
III. Unclassified – includes end-stage disease, nondiagnostic biopsies and those with inadequate material
CPI, chronic pneumonitis of infancy; DIP, desquamative cell interstitial pneumonia; NISP, nonspecific interstitial pneumonia; PAP, pulmonary alveolar proteinosis.
Genetics
282 www.co-pulmonarymedicine.com Volume 26  Number 3  May 2020
Karolak et al. [53] recently published a case report on
an infant with PIG, harbouring both a TBX4 variant
and a CTNNB1 mutation (associated with intellec-
tual disability and neurodevelopmental abnormali-
ties). The authors state that a heterozygous TBX4
variant alone may not be sufficient to cause lung
disease and suggest that mixed phenotypes may be
due to complex compound inheritance [54]. In
addition, environmental and maternal/pregnancy-
related factors may also influence the severity of the
clinical phenotype [55].
DIAGNOSTICS
Characterising chILD is difficult especially in neo-
nates [48]. Symptoms are nonspecific and neonatal
presentation will complicate the diagnostic process.
For a long time, lung biopsy for histopathological
analyses has been the ultimate diagnostic, limited
by high procedural risks and often low diagnostic
yield. Genetic testing is gaining ground due to the
identification of an increasing number of genetic
causes for several interstitial lung diseases [48]. The
presence of a certain mutation can have profound
effects for clinical decisionmaking: the dismal prog-
nosis of a FOXF1 mutation causing ACDMPV will
affect treatment decisions in a neonate dependent
on intensive ventilatory support and will avoid the
otherwise required lung biopsy [50
&&
]. Standard tes-
ting for TBX4 variants in neonates with respiratory
insufficiency has been proposed: Vincent et al. [50
&&
]
proposed to screen infants with AcDys, CAD or
other lung hypoplasias onTBX4 variants when there
is a family history of PAH. However, as long as the
prevalence and incidence of TBX4 variants in neo-
nates and the consequences in terms of treatment
strategies are not defined, the role of standard tes-




During the most recent World Symposium on Pul-
monary Hypertension in 2018, the clinical classifi-
cation of PH was updated [25]. In this classification,
unexplained PAH-associated TBX4 mutations are
assigned to group 1 PAH (HPAH). The Pediatric Task
Force introduced inGroup 3: PHdue to lung diseases
and/or hypoxia, a subclass ‘PH associated with
developmental lung disease’, in order to accommo-
date neonatal PH (other than PPHN) in the classifi-
cation. Now, as TBX4 variants are frequently
associated with developmental lung diseases, the
appropriate classification of an infant or child with
a TBX4 variant and PH becomes more complicated
and may be hazardous. This forces the diagnosing
physician to a meticulous assessment of any lung
disease and, if present, its causal role in the presence
of PH. This is obviously a challenging task in small
infants, but crucial in defining optimal treatment
strategy.
CONCLUSION
Animal studies have demonstrated an important
role of the TBX4 gene in the embryonic develop-
ment of limbs and tail mesoderm, the lung mesen-
chyme and the genital papilla [5,9]. The clinical
phenotype of TBX4 variants in humans has
expanded from bone disorders to vascular and
parenchymal lung diseases and is likely to expand
further. The enrichment of TBX4 variants in PAH
justifies inclusion of this gene in genetic analyses in
patients with PAH. Further, TBX4 variants have
shown to contribute to diffuse lung diseases, espe-
cially but not exclusively in neonates, and seems to
be multifaced. Importantly, the exact genotype-
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